Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cell-Based Therapy for Cerebral Palsy: A Puzzle in Progress Publisher



Nouri M1 ; Zarrabi M2 ; Masoumi S3 ; Khodadoust E1 ; Majmaa A4 ; Amanat M5 ; Ashrafi MR6, 7 ; Vosough M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. R&D Department, Royan Stem Cell Technology Company, Tehran, Iran
  2. 2. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  3. 3. Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Children’s Medical Center, Pediatrics Center of Excellence, Tehran, Iran
  5. 5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
  6. 6. Pediatric Neurology Division, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Pediatric Cell, Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Cell Journal Published:2024


Abstract

Cell-based therapy has shown promising outcomes in the treatment of cerebral palsy (CP). However, there is no consensus on a standard therapeutic protocol regarding the source of cells, optimal cell dose, timing and frequency of cell injections, route of administration, or the use of combination therapy. This lack of consensus necessitates a comprehensive investigation to clarify these crucial yet undefined factors in cell-based therapy for CP patients. In this commentary, we discuss and compare the trends in Gross Motor Function Measure-66 following intrathecal injection of umbilical cord blood mononuclear cells (UCB-MNCs) and umbilical cord tissue mesenchymal stromal cells (UCT-MSCs) in children with CP. Our study revealed that MNC injections led to earlier improvements in gross motor function, whereas MSC applications resulted in more sustainable changes. These findings provide key insights into the efficacy of different cell types, which will be beneficial for future studies and for refining cell-based therapy protocols for CP treatment. © 2024 Royan Institute (ACECR). All rights reserved.
Related Docs
1. Cord Blood Treatment for Children With Cerebral Palsy: Individual Participant Data Meta-Analysis, Pediatrics (2025)
2. Positive and Negative Cell Therapy in Randomized Control Trials for Central Nervous System Diseases, International Review of Neurobiology (2023)
3. The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Individuals With Spastic Cerebral Palsy: A Randomized Double-Blind Sham-Controlled Clinical Trial, BMC Neurology (2022)
4. Advances in Neurorestoratology—Current Status and Future Developments, International Review of Neurobiology (2023)
5. The 2022 Yearbook of Neurorestoratology, Journal of Neurorestoratology (2023)
6. Clinical Cell Therapy Guidelines for Neurorestoration (Ianr/Canr 2022), Journal of Neurorestoratology (2022)
7. Clinical and Imaging Outcomes After Intrathecal Injection of Umbilical Cord Tissue Mesenchymal Stem Cells in Cerebral Palsy: A Randomized Double-Blind Sham-Controlled Clinical Trial, Stem Cell Research and Therapy (2021)
8. Cell-Based and Gene-Based Therapy Approaches in Neuro-Orthopedic Disorders: A Literature Review, Regenerative Engineering and Translational Medicine (2023)
Experts (# of related papers)
View all Related Experts
Hooshang Saberi (4)
Mahmoudreza Ashrafi (3)